Advertisement


Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy

ESMO Virtual Congress 2020

Advertisement

Thierry Andre, MD, of Hôpital Saint-Antoine, discusses phase III KEYNOTE-177 findings on the reduced risk of disease progression or death in patients receiving pembrolizumab monotherapy as a first-line treatment of microsatellite instability–high and/or mismatch repair–deficient metastatic colorectal cancer (Abstract 396O).



Related Videos

Skin Cancer
Immunotherapy

Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, wh...

Head and Neck Cancer
Immunotherapy

Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease

Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses primary results of the phase III JAVELIN trial of locally advanced squamous cell carcinoma of the h...

Skin Cancer
Immunotherapy

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-yea...

Breast Cancer

Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in ...

Lung Cancer

Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy

Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherap...

Advertisement

Advertisement



Advertisement